Skip to main content

Advertisement

SpringerLink
Log in

Tumor Prognostic Factors and the Challenge of Developing Predictive Factors

  • Neuro-oncology (MR Gilbert, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Histopathologic classification has been widely used to type and grade primary brain tumors. However, the diverse behavior of primary brain tumors has made prognostic determinations based purely on clinical and histopathologic variables difficult. Recent advances in the molecular genetics of brain tumors have helped to explain the witnessed heterogeneity regarding response to treatment, time to progression, and overall survival. Additionally, there has been interest in identifying predictive factors to help direct patients to therapeutic interventions specific to their tumor and patient biology. Further identification of both prognostic and predictive biomarkers will make possible better patient stratification and individualization of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual report to the nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338–66.

    Article  PubMed  Google Scholar 

  2. Bammler T, Beyer RP, Bhattacharya S, Boorman GA, Boyles A, Bradford BU, et al. Standardizing global gene expression analysis between laboratories and across platforms. Nat Methods. 2005;2(5):351–6.

    Article  PubMed  CAS  Google Scholar 

  3. Wen PY, Fine HA, Black PM, Shrieve DC, Alexander 3rd E, Loeffler JS. High-grade astrocytomas. Neurol Clin. 1995;13(4):875–900.

    PubMed  CAS  Google Scholar 

  4. Curran Jr WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704–10.

    Article  PubMed  Google Scholar 

  5. Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran Jr WJ, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;81(3):623–30.

    Article  PubMed  Google Scholar 

  6. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  PubMed  CAS  Google Scholar 

  7. Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol. 2007;38(5):679–87.

    Article  PubMed  CAS  Google Scholar 

  8. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–5.

    Article  PubMed  CAS  Google Scholar 

  9. Ichimura K, Ohgaki H, Kleihues P, Collins VP. Molecular pathogenesis of astrocytic tumours. J Neurooncol. 2004;70(2):137–60.

    Article  PubMed  Google Scholar 

  10. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 2004;14(2):121–30.

    Article  PubMed  CAS  Google Scholar 

  11. Riemenschneider MJ, Knobbe CB, Reifenberger G. Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer. 2003;104(6):752–7.

    Article  PubMed  CAS  Google Scholar 

  12. Eley GD, Reiter JL, Pandita A, Park S, Jenkins RB, Maihle NJ, et al. A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neuro Oncol. 2002;4(2):86–94.

    PubMed  CAS  Google Scholar 

  13. Rasheed BK, McLendon RE, Friedman HS, Friedman AH, Fuchs HE, Bigner DD, et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene. 1995;10(11):2243–6.

    PubMed  CAS  Google Scholar 

  14. Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, Maurer M, et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer. 2005;42(1):68–77.

    Article  PubMed  CAS  Google Scholar 

  15. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. 1994;145(5):1175–90.

    PubMed  CAS  Google Scholar 

  16. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol. 2003;62(2):111–26.

    PubMed  CAS  Google Scholar 

  17. Hartmann C, Johnk L, Kitange G, Wu Y, Ashworth LK, Jenkins RB, et al. Transcript map of the 3.7-Mb D19S112–S246 candidate tumor suppressor region on the long arm of chromosome 19. Cancer Res. 2002;62(14):4100–8.

    PubMed  CAS  Google Scholar 

  18. Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, Portier BP, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 2000;64(1):44–50.

    Article  PubMed  CAS  Google Scholar 

  19. Huang B, Starostik P, Kuhl J, Tonn JC, Roggendorf W. Loss of heterozygosity on chromosome 22 in human ependymomas. Acta Neuropathol. 2002;103(4):415–20.

    Article  PubMed  CAS  Google Scholar 

  20. Suarez-Merino B, Hubank M, Revesz T, Harkness W, Hayward R, Thompson D, et al. Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1–q13.3. Neuro Oncol. 2005;7(1):20–31.

    Article  PubMed  CAS  Google Scholar 

  21. Oskam NT, Bijleveld EH, Hulsebos TJ. A region of common deletion in 22q13.3 in human glioma associated with astrocytoma progression. Int J Cancer. 2000;85(3):336–9.

    Article  PubMed  CAS  Google Scholar 

  22. Ino Y, Silver JS, Blazejewski L, Nishikawa R, Matsutani M, von Deimling A, et al. Common regions of deletion on chromosome 22q12.3–q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol. 1999;58(8):881–5.

    Article  PubMed  CAS  Google Scholar 

  23. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, et al. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene. 2003;22(48):7687–94.

    Article  PubMed  CAS  Google Scholar 

  24. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res. 1999;59(17):4228–32.

    PubMed  CAS  Google Scholar 

  25. Caskey LS, Fuller GN, Bruner JM, Yung WK, Sawaya RE, Holland EC, et al. Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling. Histol Histopathol. 2000;15(3):971–81.

    PubMed  CAS  Google Scholar 

  26. Huang H, Colella S, Kurrer M, Yonekawa Y, Kleihues P, Ohgaki H. Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res. 2000;60(24):6868–74.

    PubMed  CAS  Google Scholar 

  27. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000;60(23):6617–22.

    PubMed  CAS  Google Scholar 

  28. Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res. 2001;7(8):2387–95.

    PubMed  CAS  Google Scholar 

  29. Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene. 2005;24(47):7073–83.

    Article  PubMed  CAS  Google Scholar 

  30. Raza SM, Fuller GN, Rhee CH, Huang S, Hess K, Zhang W, et al. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin Cancer Res. 2004;10(1 Pt 1):212–21.

    Article  PubMed  CAS  Google Scholar 

  31. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.

    Article  PubMed  CAS  Google Scholar 

  32. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci USA. 1994;91(11):5022–6.

    Article  PubMed  CAS  Google Scholar 

  33. Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 2008;9:387–402.

    Article  PubMed  CAS  Google Scholar 

  34. Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008;24(3):133–41.

    Article  PubMed  CAS  Google Scholar 

  35. McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis M, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.

    Article  CAS  Google Scholar 

  36. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510–22.

    Article  PubMed  CAS  Google Scholar 

  37. Cerami E, Demir E, Schultz N, Taylor BS, Sander C. Automated network analysis identifies core pathways in glioblastoma. PLoS One. 2010;5(2):e8918.

    Article  PubMed  CAS  Google Scholar 

  38. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA. 2009;302(3):261–75.

    Article  PubMed  CAS  Google Scholar 

  39. Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, et al. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4(11):e7752.

    Article  PubMed  CAS  Google Scholar 

  40. • Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98–110. Results were validated using TCGA data.

    Article  PubMed  CAS  Google Scholar 

  41. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95(25):14863–8.

    Article  PubMed  CAS  Google Scholar 

  42. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics. 2005;21(13):3017–24.

    Article  PubMed  CAS  Google Scholar 

  43. •• Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol. 2010;12(1):49–57. Microarray data from four independent sets were used and consensus genes were identified. Results were validated using TCGA data.

    Article  PubMed  CAS  Google Scholar 

  44. • Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, et al. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol. 2012;123(5):727–38. Four institutional gene expression datasets were used for signature discovery and validated using an independent dataset of 84 infratentorial ependymomas.

    Article  PubMed  CAS  Google Scholar 

  45. Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: From disarray to consolidation and consensus. Nat Rev Genet. 2006;7(1):55–65.

    Article  PubMed  CAS  Google Scholar 

  46. Baker J. Genomic Health, Inc. Pharmacogenomics. 2007;8(4):397–9.

    Article  PubMed  CAS  Google Scholar 

  47. Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006;7:278.

    Article  PubMed  CAS  Google Scholar 

  48. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res. 2001;61(18):6885–91.

    PubMed  CAS  Google Scholar 

  49. Kim S, Dougherty ER, Shmulevich I, Hess KR, Hamilton SR, Trent JM, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther. 2002;1(13):1229–36.

    PubMed  CAS  Google Scholar 

  50. Dai B, Kang SH, Gong W, Liu M, Aldape KD, Sawaya R, et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene. 2007;26(42):6212–9.

    Article  PubMed  CAS  Google Scholar 

  51. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 2006;66(7):3593–602.

    Article  PubMed  CAS  Google Scholar 

  52. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003;63(7):1602–7.

    PubMed  CAS  Google Scholar 

  53. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65(5):1678–86.

    Article  PubMed  CAS  Google Scholar 

  54. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9(3):157–73.

    Article  PubMed  CAS  Google Scholar 

  55. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002;62(15):4364–8.

    PubMed  CAS  Google Scholar 

  56. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65(5):1678–86.

    Article  PubMed  CAS  Google Scholar 

  57. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res. 2005;11(6):2258–64.

    Article  PubMed  CAS  Google Scholar 

  58. Liang Y, Bollen AW, Aldape KD, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. BMC Cancer. 2006;6(1):97.

    Article  PubMed  CAS  Google Scholar 

  59. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA. 2005;102(16):5814–9.

    Article  PubMed  CAS  Google Scholar 

  60. Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, et al. A genome-wide screen reveals functional gene clusters in the cancer genome and identifies EphA2 as a mitogen in glioblastoma. Cancer Res. 2006;66(22):10815–23.

    Article  PubMed  CAS  Google Scholar 

  61. Persson O, Krogh M, Saal LH, Englund E, Liu J, Parsons R, et al. Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. J Neurooncol. 2007;85(1):11–24.

    Article  PubMed  CAS  Google Scholar 

  62. Radiation Therapy Oncology Group. Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma. 2009–2012. http://www.clinicaltrials.gov/ct2/show/NCT00884741?term=rtog+0825&rank=1

  63. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, et al. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics. 2006;6(23):6277–87.

    Article  PubMed  CAS  Google Scholar 

  64. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, et al. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res. 2007;6(2):559–70.

    Article  PubMed  CAS  Google Scholar 

  65. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z. Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B. 2005;6(1):4–10.

    Article  PubMed  CAS  Google Scholar 

  66. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, et al. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008;54(4):713–22.

    Article  PubMed  CAS  Google Scholar 

  67. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–6.

    Article  PubMed  CAS  Google Scholar 

  68. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63(11):2742–6.

    PubMed  CAS  Google Scholar 

  69. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25(16):2288–94.

    Article  PubMed  CAS  Google Scholar 

  70. Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol. 2009;19(3):142–9.

    Article  PubMed  Google Scholar 

  71. •• Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. High-density oligonucleotide arrays and next-generation sequencing were used to identify transcripts for 23,219 from 20,661 genes. IDH mutations are more likely in younger patients and those with secondary glioblastoma.

    Article  PubMed  CAS  Google Scholar 

  72. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.

    Article  PubMed  CAS  Google Scholar 

  73. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597–602.

    Article  PubMed  CAS  Google Scholar 

  74. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002–7.

    Article  PubMed  CAS  Google Scholar 

  75. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482–90.

    Article  PubMed  CAS  Google Scholar 

  76. Phillips TM, McBride WH, Pajonk F. The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98(24):1777–85.

    Article  PubMed  Google Scholar 

  77. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20(8):2076–84.

    Article  PubMed  Google Scholar 

  78. Watson MA, Perry A, Budhraja V, Hicks C, Shannon WD, Rich KM. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res. 2001;61(5):1825–9.

    PubMed  CAS  Google Scholar 

  79. Mukasa A, Ueki K, Ge X, Ishikawa S, Ide T, Fujimaki T, Nishikawa R, Asai A, Kirino T, Aburatani H. Selective expression of a subset of neuronal genes in oligodendroglioma with chromosome 1p loss. Brain Pathol. 2004;14(1):34–42.

    Article  PubMed  CAS  Google Scholar 

  80. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer. 2008;7:41.

    Article  PubMed  CAS  Google Scholar 

  81. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, et al. Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer. 2006;119(4):792–800.

    Article  PubMed  CAS  Google Scholar 

  82. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res. 2005;11(3):1119–28.

    PubMed  CAS  Google Scholar 

  83. Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, et al. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology. 2006;66(11):1661–7.

    Article  PubMed  CAS  Google Scholar 

  84. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66(20):9852–61.

    Article  PubMed  CAS  Google Scholar 

  85. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24(18):2707–14.

    Article  PubMed  CAS  Google Scholar 

  86. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012. doi:10.1200/JCO.2012.43.2674.

  87. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715–22.

    Article  PubMed  CAS  Google Scholar 

  88. van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group study 26951. J Clin Oncol. 2012. doi:10.1200/JCO.2012.43.2229.

  89. Korshunov A, Neben K, Wrobel G, Tews B, Benner A, Hahn M, et al. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Am J Pathol. 2003;163(5):1721–7.

    Article  PubMed  CAS  Google Scholar 

  90. Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005;8(4):323–35.

    Article  PubMed  CAS  Google Scholar 

  91. Modena P, Lualdi E, Facchinetti F, Veltman J, Reid JF, Minardi S, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006;24(33):5223–33.

    Article  PubMed  CAS  Google Scholar 

  92. Sowar K, Straessle J, Donson AM, Handler M, Foreman NK. Predicting which children are at risk for ependymoma relapse. J Neurooncol. 2006;78(1):41–6.

    Article  PubMed  Google Scholar 

  93. de Bont JM, Kros JM, Passier MM, Reddingius RE. Sillevis Smitt PA, Luider TM, den Boer ML, Pieters R: Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol. 2008;10:648–60.

    Article  PubMed  CAS  Google Scholar 

  94. Lukashova-v Zangen I, Kneitz S, Monoranu CM, Rutkowski S, Hinkes B, Vince GH, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol. 2007;113(3):325–37.

    Article  PubMed  CAS  Google Scholar 

  95. Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, et al. Identification of microRNAs as potential prognostic markers in ependymoma. PLoS One. 2011;6(10):e25114.

    Article  PubMed  CAS  Google Scholar 

  96. Michalowski MB, de Fraipont F, Michelland S, Entz-Werle N, Grill J, Pasquier B, et al. Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. Cancer Genet Cytogenet. 2006;166(1):74–81.

    Article  PubMed  CAS  Google Scholar 

  97. Rahman R, Osteso-Ibanez T, Hirst RA, Levesley J, Kilday JP, Quinn S, et al. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. Mol Cancer Ther. 2010;9(9):2568–81.

    Article  PubMed  CAS  Google Scholar 

  98. CBTRUS. Statistical report: primary brain tumors in the United States, 2000–2004. In; 2008.

  99. Gabeau-Lacet D, Engler D, Gupta S, Scangas GA, Betensky RA, Barker 2nd FG, et al. Genomic profiling of atypical meningiomas associates gain of 1q with poor clinical outcome. J Neuropathol Exp Neurol. 2009;68(10):1155–65.

    Article  PubMed  CAS  Google Scholar 

  100. Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994;6(2):180–4.

    Article  PubMed  CAS  Google Scholar 

  101. Sulman EP, Dumanski JP, White PS, Zhao H, Maris JM, Mathiesen T, et al. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res. 1998;58(15):3226–30.

    PubMed  CAS  Google Scholar 

  102. Sulman EP, White PS, Brodeur GM. Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34. Oncogene. 2004;23(4):1014–20.

    Article  PubMed  CAS  Google Scholar 

  103. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, et al. Molecular signatures define two main classes of meningiomas. Mol Cancer. 2007;6:64.

    Article  PubMed  CAS  Google Scholar 

  104. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, et al. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res. 2010;16(16):4155–64.

    Article  PubMed  CAS  Google Scholar 

  105. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, et al. Genomic landscape of meningiomas. Brain Pathol. 2010;20(4):751–62.

    Article  PubMed  CAS  Google Scholar 

  106. Bie L, Zhao G, Ju Y, Zhang B. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence. Cancer Genet. 2011;204(10):536–40.

    Article  PubMed  CAS  Google Scholar 

  107. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001;29(2):143–52.

    Article  PubMed  CAS  Google Scholar 

  108. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, et al. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004;64(9):3103–11.

    Article  PubMed  CAS  Google Scholar 

  109. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415(6870):436–42.

    Article  PubMed  CAS  Google Scholar 

  110. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24(12):1924–31.

    Article  PubMed  CAS  Google Scholar 

  111. •• Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29(11):1424–30. Molecular classification of meduloblastoma, validated with 102 patients from three independent cohorts.

    Article  PubMed  Google Scholar 

  112. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, et al. International network of cancer genome projects. Nature. 2010;464(7291):993–8.

    Article  PubMed  CAS  Google Scholar 

  113. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol. 2011;29(11):1400–7.

    Article  PubMed  Google Scholar 

  114. Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010;2(51):51ra70.

    Article  PubMed  CAS  Google Scholar 

  115. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361(12):1173–8.

    Article  PubMed  CAS  Google Scholar 

  116. • Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29(11):1408–14. The four subgroups were validated using immunohistochemistry.

    Article  PubMed  Google Scholar 

  117. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol. 2012;8(6):340–51.

    Article  PubMed  CAS  Google Scholar 

  118. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488(7409):100–5.

    Article  PubMed  CAS  Google Scholar 

  119. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.

    Article  PubMed  CAS  Google Scholar 

  120. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn M-J, et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). In: European Society for Medical Oncology 2012 Congress. Vienna, Austria; Presented on September 30, 2012: LBA1_PR.

  121. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343(19):1350–4.

    Article  PubMed  CAS  Google Scholar 

  122. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

    Article  PubMed  CAS  Google Scholar 

  123. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.

    Article  PubMed  CAS  Google Scholar 

  124. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.

    Article  PubMed  CAS  Google Scholar 

  125. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12(2):116–21.

    Article  PubMed  CAS  Google Scholar 

  126. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13(7):707–15.

    Article  PubMed  CAS  Google Scholar 

  127. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462–6.

    Article  PubMed  CAS  Google Scholar 

  128. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3–8.

    Article  PubMed  CAS  Google Scholar 

  129. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008;90(1):89–97.

    Article  PubMed  CAS  Google Scholar 

  130. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26(34):5603–9.

    Article  PubMed  CAS  Google Scholar 

  131. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353(19):2012–24.

    Article  PubMed  CAS  Google Scholar 

  132. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268–74.

    Article  PubMed  CAS  Google Scholar 

  133. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 2001;8(1):3–9.

    Article  PubMed  CAS  Google Scholar 

  134. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23(9):2020–7.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX, 77030, USA

    Emma B. Holliday & Erik P. Sulman

Authors
  1. Emma B. Holliday
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erik P. Sulman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Erik P. Sulman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holliday, E.B., Sulman, E.P. Tumor Prognostic Factors and the Challenge of Developing Predictive Factors. Curr Oncol Rep 15, 33–46 (2013). https://doi.org/10.1007/s11912-012-0283-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-012-0283-3

Keywords

Search

Navigation